Polymorphisms in MIR27A associated with early-onset toxicity in fluoropyrimidine-based chemotherapy

Clinical Cancer Research

Volumn 21, Issue 9, 2015, Pages 2038-2044

  Amstutz, Ursula ^a   Offer, Steven M ^b   Sistonen, Johanna ^a   Joerger, Markus ^c   Diasio, Robert B ^b   Largiader, Carlo R ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b MAYO CLINIC CANCER CENTER   (United States)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CAPECITABINE; CYTOSINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; GUANINE; MICRORNA; MICRORNA 27A; OXALIPLATIN; THYMINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRN27 MICRORNA, HUMAN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DPYD GENE; DRY SKIN; ENZYME ACTIVITY; FEMALE; GENE; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HAIR LOSS; HAND FOOT SYNDROME; HETEROZYGOTE; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MIR27A GENE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEOPLASM; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTOPENIA; VOMITING; ADOLESCENT; GENETICS; MIDDLE AGED; NEOPLASMS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84928131723     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2817     Document Type: Article

References (32)

1. Amstutz U, Froehlich TK, Largiadér CR. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 2011;12:1321-36.
2. Ezzeldin H, Diasio RB. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-Threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 2004;4:181-9.
3. Froehlich TK, Amstutz U, Aebi S, Joerger M, Largiadér CR. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer 2015;136:730-9.
4. Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther 2013;94:640-5.
5. SchwabM, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008;26:2131-8.
6. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions, and therapy. Trends Mol Med 2014;20:460-9.
7. To KKW. MicroRNA: A prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy. J Biomed Sci 2013;20:99.
8. Offer SM, Butterfield GL, Jerde CR, Fossum CC, Wegner NJ, Diasio RB. microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites. Mol Cancer Ther 2014;13:742-51.
9. Hirota T, Date Y, Nishibatake Y, Takane H, Fukuoka Y, Taniguchi Y, et al. Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues. Lung Cancer 2012;77: 16-23.
10. Wang Q, Li D-C, Li Z-F, Liu C-X, Xiao Y-M, Zhang B, et al. Upregulation of miR-27a contributes to the malignant transformation of human bronchial epithelial cells induced by SV40 small T antigen. Oncogene 2011;30:3875-86.
11. Liu T, Tang H, Lang Y, Liu M, Li X. MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett 2009;273: 233-42.
12. Eitan R, KushnirM, Lithwick-Yanai G, David MB, HoshenM, Glezerman M, et al. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol 2009;114:253-9.
13. Li J, Wang Y, Song Y, Fu Z, Yu W. miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells. Mol Cancer 2014;13:193.
14. Li Z, Hu S, Wang J, Cai J, Xiao L, Yu L, et al. MiR-27a modulates MDR1/Pglycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol 2010;119:125-30.
15. Wang Z, Sun X, Wang Y, Liu X, Xuan Y, Hu S. Association between miR-27a genetic variants and susceptibility to colorectal cancer. Diagn Pathol 2014;9:146.
16. Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu C-G, et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 2008; 76:582-8.
17. Noratto GD, Jutooru I, Safe S, Angel-Morales G, Mertens-Talcott SU. The drug resistance suppression induced by curcuminoids in colon cancer SW-480 cells is mediated by reactive oxygen species-induced disruption of the microRNA-27a-ZBTB10-Sp axis. Mol Nutr Food Res 2013;57: 1638-48.
18. Xiong X-D, Luo X-P, Cheng J, Liu X, Li E-M, Zeng L-Q. A genetic variant in pre-miR-27a is associated with a reduced cervical cancer risk in southern Chinese women. Gynecol Oncol 2014;132:450-4.
19. Stenholm L, Stoehlmacher-Williams J, Al-Batran S-E, Heussen N, Akin S, Pauligk C, et al. Prognostic role of microRNA polymorphisms in advanced gastric cancer: A translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Ann Oncol 2013;24: 2581-8.
20. Xu J, Yin Z, ShenH, Gao W, Qian Y, PeiD, et al. A genetic polymorphismin pre-miR-27a confers clinical outcome of non-small cell lung cancer in a Chinese population. PLoS ONE 2013;8:e79135.
21. Yang R, Burwinkel B. A bias in genotyping the miR-27a rs895819 and rs11671784 variants. Breast Cancer Res Treat 2012;134:899-901.
22. Raymond M, Rousset F. GENEPOP (version 1.2): population genetics software for exact tests and ecumenicism. J Heredity. Am Genetic Assoc 1995;86:248-9.
23. Harrell FE. rms: Regression Modeling Strategies. R package version 4.1-1. 2009 Available from http://CRAN.R-project.org/package1/4rms
24. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013. Available from: http://www.R-project.org/
25. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: An open-source package for R and Sφ to analyze and compare ROC curves. BMC Bioinformatics 2011; 12:77
26. The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1, 092 human genomes. Nature 2012;491:56-65.
27. Lee AM, Shi Q, Pavey E, Alberts SR, SargentDJ, Sinicrope FA, et al.DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst 2014;106:dju298.
28. Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, et al. Geneticmarkers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-Analysis. J Clin Oncol 2014;32:1031-9.
29. Zhang H, Li M, Han Y, Hong L, Gong T, Sun L, et al. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci 2010;55:2545-51.
30. Kang MH, Reynolds CP. Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009;15:1126-32.
31. Zhao X, Yang L, Hu J. Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 2011;30:55.
32. Cochrane DR, Cittelly DM, Richer JK. Steroid receptors and microRNAs: relationships revealed. Steroids 2011;76:1-10.